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Minor Parameters Needed for Individual-Dose Calculations
This brief report documents the selection of parameters needed to support individual-dose calculations from 131 I released into the environment with gaseous effluents from the Mayak Production Association.
Age-dependent internal dose-conversion factors for 131 I
Normalized factors for converting inhaled or ingested radionuclides are presented in Tables 1 and 2 . These were prepared using the computer code package DCAL (Eckerman et al. 2006 ). The factors are provided for six age groups (3 month, 1 year, 5 year, 10 year, 15 year, and adult). The inhalation factors are for the International Commission on Radiological Protection (ICRP)inhalation Class F. The set of dosimetric models is generally the same as that used in the ICRP's series of documents on doses to members of the public, as summarized in ICRP Publication 72 (1996) . The biokinetic libraries used by DCAL include the latest ICRP model of the respiratory tract as described in ICRP Publication 66 (1994) ; the ICRP's gastrointestinal tract model first used in ICRP Publication 30 (1979) ; and the urinary bladder voiding model described in ICRP Publication 67 (1993) . The nuclear decay library contains nuclear decay data currently used by the ICRP (1983) and the Medical Internal Radiation Dose (MIRD) Committee of the Society of Nuclear Medicine (Weber et al. 1989 ) and information on the energies and intensities of the radiations associated with spontaneous nuclear transformation.
The photon specific absorbed fraction library is based on the data of Cristy and Eckerman (1987; as currently used by the ICRP. Organ masses for adults are taken from ICRP Publication 23 (Reference Man, ICRP 1975) and, for children, the values are taken from the phantoms of Cristy and Eckerman (1987; , which are based on data from ICRP Publication 23.
The calculations for Tables 1 and 2 were made with the assumption that the  131 I decay   progeny   131 Xe is rapidly eliminated from the human body with a transfer rate of 1000 day -1 .
Uptake from gut to blood (f 1 ) is assumed to be 1.0 for all ages. Because the half-life of 131 I is short, these factors can be applied as annual (or even monthly) doses.
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Fetal thyroid-dose-conversion factors for 131 I
Ordinarily, our bias is to choose model results presented by the ICRP. However, in the case of uptake of radioiodine by the fetus that results from the ingestion or inhalation of radioiodine by the mother, we believe that the ICRP model is incorrect. The following explains our objections to the ICRP model and our choice of an alternate model due to Watson (1992) .
The latter model had previously been adopted by the NCRP (1998).
A number of models (Johnson 1982; Basic et al. 1988; Zanzonico and Becker 1991; Watson 1992; NCRP 1998; Berkovski 1999a,b; ICRP 2001) designed to provide dose coefficients for the case of dose to the fetal thyroid resulting from intake of 131 I by the mother were examined. The majority of these models are based on Johnson's model with further considerations of additional experimental data. The dependences of in utero fetal thyroid dose as a function of fetal age at the time of the mother's intake had a similar tendency for all models with the exception of the model presented by the ICRP, which was developed by Berkovski (see Fig. 1 ). As distinguished from the other models, the ICRP model shows a constant increase of dose coefficient versus fetal age. In addition, the increase of the dose coefficient at early fetal age in the range of 11 to 20 weeks after conception in the ICRP model is much less than that in the other models.
Also, a high value of 9% for fetal uptake of 131 I at term, which was used in the development of the ICRP model, was based on one pooled result in guinea pigs (Palmer and Preece 1998) rather than in the human fetus. Other authors (Evans et al. 1967; Stieve 1987) have reported substantially lower values for human fetal uptake in late gestation. The authors of many publications (Johnson 1982; Stieve 1987; Basic et al. 1988; Stabin et al. 1991; Zanzonico and Becker 1991; Watson 1992) concluded that although fetal uptake increases rapidly from the third month to term, the peak concentration of 131 I is reached at 20 to 24 weeks; thereafter it decreases, because the mass of the gland increases more rapidly than does the uptake. And, of course, the dose coefficient at the point of birth must be zero, as there is no time for the mother's intake to reach the fetus. In addition, the publications (Johnson 1982; Basic et al. 1988; Ng et al. 1991; Simon et al. 1990; Zanzonico and Becker 1991; Watson 1992) show more a rapid increase of dose coefficient versus fetal age in the range of 11 to 20 weeks compared to that in ICRP (2001).
After analyzing data on the measurements of 131 I in 30 human fetal thyroids, Basic et al. (1988) found that the maximum concentration of 131 I in human fetal thyroid was observed at about the fifth month of gestation with further substantial decrease.
Taking into account the information mentioned above and the inconsistency of the ICRP model with human data, we chose not to use the ICRP model. Rather we have chosen to use the model adopted by the NCRP (1998), which is based on the model of Watson (1992) . We believe that the use of this model provides the best consistency with data from human feti. As indicated in Fig. 1 , however, this model is not a continuous function. In order to use the model for our purposes we have interpolated the values given by the NCRP; the results of these interpolations are given in Fig. 2 and in Table 3 . The sharp decrease of the dose-coefficient near and at term is explained by the fact that, as term is approached, less and less of the iodine ingested by the mother can reach the fetus.
The values given can be considered as geometric means; a value of 2.2 is suggested for the value of the accompanying geometric standard deviation. Transfer of radioiodine to human-breast milk The second group included those with much higher excretions. The second group, termed the "normal-excretion" group, had transfers of iodine-to-milk that were more than ten-fold higher than in the "low-excretion" group. The derived milk-transfer-coefficient data for the low-and normal-excretion groups fitted to lognormal distributions gave geometric means, (geometric Various biologic and metabolic parameters have been considered as possibly important to the excretion of radioiodine via breast milk, one being the milk-production rate. However, the daily volume of milk produced by lactating women and ingested by infants averages over a narrow range, from about 750 to 800 mL d -1 (IOM 1991) . This volume varies little among women with different caloric intakes, nutritional status, age, parity, and anthropometric indices though the volume of milk secreted declines rapidly if suckling is discontinued. Thus, maternal milk-production rate is not a significant determinant of iodine transfer to milk.
Rate of consumption of breast milk by the infant
Based on the information above, the rate of consumption of breast milk by an infant should be taken as an uniform distribution of 750 to 800 mL day -1 .
Inhalation rates
It is well known that inhalation rates change substantially due to a variety of factors, which include age, weight, health, and activity level. Table 4 .
It is well to remember that inhalation is not one of the primary pathways of dose to man for 131 I; however, for a person who does not drink milk or eat fresh vegetables, it may be the only pathway of internal exposure. Thus, it would be necessary to include this pathway in any projected epidemiologic study of thyroid disease. 
Ratio of indoor air concentration-to-outdoor air concentration
There are not many simultaneous measurements of indoor and outdoor air concentrations of airborne radionuclides. A general rule of thumb has been that the ratio is about 0.5; this "lore" appears to be based more on supposition than on fact. As typical for the period of time of interest, there would not have been air conditioning in homes in Ozersk. And typically, Russian homes tend to be overheated in wintertime with regulation achieved by opening windows. Or, if homes are underheated, it is typically due to air exchange being higher than desirable. Thus, averaged over a month it seems likely that the ratio of indoor to outdoor concentration would have been closer to 1.0 rather than 0.5.
For use in this assessment, we have adopted the values given in Apostoaei (2005) ; the values are given in Table 5 . 
